XenoPort Inc (XNPT)

7.07
0.05 0.71
Prev Close 7.02
Open 7.04
Day Low/High 7.02 / 7.07
52 Wk Low/High 3.35 / 7.86
Volume 2.62M
Avg Volume 1.64M
Exchange
Shares Outstanding 63.53M
Market Cap 449.13M
EPS -1.30
Div & Yield N.A. (N.A)
XenoPort Announces FDA Agreement On A Special Protocol Assessment For A Pivotal Phase 3 Clinical Trial Of Arbaclofen Placarbil For Spasticity In MS Patients

XenoPort Announces FDA Agreement On A Special Protocol Assessment For A Pivotal Phase 3 Clinical Trial Of Arbaclofen Placarbil For Spasticity In MS Patients

XenoPort, Inc. (Nasdaq: XNPT) announced today that it had reached agreement with the U.

XenoPort Announces Presentation Of Preclinical Data For Novel Fumarate Analog XP23829 At The 63rd Annual Meeting Of The American Academy Of Neurology

XenoPort Announces Presentation Of Preclinical Data For Novel Fumarate Analog XP23829 At The 63rd Annual Meeting Of The American Academy Of Neurology

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on a preclinical product candidate, XP23829, at the 63 rd Annual Meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii.

Cushioning for Commodities

Expiration weeks are better known for shakeouts than major reversals, so commodities, including crude oil, are more likely to bend into Friday's close rather than roll over or break down.

XenoPort Stock Falls On Unusually High Volume (XNPT)

XenoPort Stock Falls On Unusually High Volume (XNPT)

XenoPort (Nasdaq:XNPT) is trading at unusually high volume Friday with 3.4 million shares changing hands. It is currently at four times its average daily volume and trading down 47 cents (-4.7%).

Buckle, Costco, Bed Bath & Beyond Are Big Movers

Buckle, Costco, Bed Bath & Beyond Are Big Movers

Buckle, Costco, Bed Bath & Beyond, Xenoport are among big market movers Thursday

XenoPort, Rite Aid: Small-Cap Winners

XenoPort, Rite Aid: Small-Cap Winners

TheStreet presents a rundown of the winners in the small-cap space during the day's trading.

GlaxoSmithKline And XenoPort Receive FDA Approval For Horizant™

GlaxoSmithKline And XenoPort Receive FDA Approval For Horizant™

GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced Wednesday that the U.

XenoPort Stock Gaps Down On Today's Open (XNPT)

XenoPort Stock Gaps Down On Today's Open (XNPT)

Shares of XenoPort (Nasdaq:XNPT) were gapping down Monday morning with an open price 13% lower than Friday's closing price. The stock closed at $6.67 yesterday and opened today's trading at $5.80.

XenoPort Reports Results From A Phase 2b Clinical Trial Of Arbaclofen Placarbil As Adjunctive Treatment For Patients With GERD

XenoPort Reports Results From A Phase 2b Clinical Trial Of Arbaclofen Placarbil As Adjunctive Treatment For Patients With GERD

XenoPort, Inc. (Nasdaq:XNPT) announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease...

XenoPort To Present At Upcoming Healthcare Conferences

XenoPort To Present At Upcoming Healthcare Conferences

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentations at the 2011 RBC Capital Markets' Healthcare Conference and the Cowen and Company 2011 Health Care...

Biotech Calendar: 2011 FDA Drug Approvals

Biotech Calendar: 2011 FDA Drug Approvals

An updated list of drug and biotech firms with drug approvals expected in 2011.

XenoPort Reports Fourth Quarter And Year-End 2010 Financial Results

XenoPort Reports Fourth Quarter And Year-End 2010 Financial Results

XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2010.

XenoPort To Release Fourth Quarter And Year-End Financial Results On February 16, 2011

XenoPort To Release Fourth Quarter And Year-End Financial Results On February 16, 2011

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will release its fourth quarter financial results on February 16, 2011 at approximately 4:30 p.

XenoPort Announces New Employment Inducement Awards

XenoPort Announces New Employment Inducement Awards

XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to three new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

Layoffs Mount in 2010: What Does It Mean for 2011?

Layoffs Mount in 2010: What Does It Mean for 2011?

The job market remains fragile in 2010, as companies lay off workers at a steady pace. Will unemployment remain depressed in 2011?

XenoPort Announces Pricing Of Public Offering Of Common Stock

XenoPort Announces Pricing Of Public Offering Of Common Stock

XenoPort, Inc. (Nasdaq: XNPT) announced today the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $7.

XenoPort Announces Proposed Public Offering Of Common Stock

XenoPort Announces Proposed Public Offering Of Common Stock

XenoPort, Inc. (Nasdaq: XNPT) announced today that it is offering to sell, subject to market and other conditions, 4,000,000 shares of its common stock pursuant to an effective shelf registration statement in an ...

XenoPort Awarded Grant From The Michael J. Fox Foundation

XenoPort Awarded Grant From The Michael J. Fox Foundation

XenoPort, Inc. (NASDAQ:XNPT) announced today that it has been awarded a grant from The Michael J.

XenoPort Reports Third Quarter Financial Results

XenoPort Reports Third Quarter Financial Results

XenoPort, Inc. (Nasdaq:XNPT) announced today financial results for the third quarter and nine months ended September 30, 2010.

GlaxoSmithKline And XenoPort Respond To FDA On Horizant™ For RLS

GlaxoSmithKline And XenoPort Respond To FDA On Horizant™ For RLS

GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) announced today that the U.

XenoPort Announces New Employment Inducement Award

XenoPort Announces New Employment Inducement Award

XenoPort, Inc. (Nasdaq: XNPT) reported today that an equity award was made to a new employee subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

XenoPort To Present At Upcoming Healthcare Conferences

XenoPort To Present At Upcoming Healthcare Conferences

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentations at the Credit Suisse 2010 Healthcare Conference and the 22 nd Annual Piper Jaffray Health Care...

XenoPort To Release Third Quarter Financial Results On November 8, 2010

XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its third quarter financial results on November 8, 2010 at approximately 6:30 a.

XenoPort Announces Presentation Of Preclinical Data For Novel Fumarate Analog XP23829 At ECTRIMS

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will present data on a new preclinical product candidate, XP23829, at the upcoming 26 th Congress of the European Committee for Treatment and Research in Multiple...

XenoPort Announces New Employment Inducement Awards

XenoPort, Inc. reported today that equity awards were made to three new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan.

XenoPort Announces Presentation Of New Data For XP21279 At World Parkinson Congress

XenoPort Announces Presentation Of New Data For XP21279 At World Parkinson Congress

XenoPort, Inc. (Nasdaq:XNPT) announced today that new data from its first clinical trial of XP21279, a Transported Prodrug of L-Dopa, in Parkinson’s disease patients will be presented at the upcoming World ...

Harwood Feffer LLP Files Class Action On Behalf Of Purchasers Of XenoPort, Inc. Securities For The Enlarged Class Period March 16, 2009 Through February 17, 2010

Harwood Feffer LLP Files Class Action On Behalf Of Purchasers Of XenoPort, Inc. Securities For The Enlarged Class Period March 16, 2009 Through February 17, 2010

The law firm of Harwood Feffer LLP announces that it filed a class action lawsuit on September 24, 2010, on behalf of purchasers of the securities of XenoPort, Inc.

XenoPort Announces Plans For Phase 3 Development Of Arbaclofen Placarbil For Spasticity

XenoPort, Inc. (Nasdaq:XNPT) announced today that it plans to move arbaclofen placarbil (AP), also known as XP19986, into Phase 3 development as a potential treatment of spasticity in multiple sclerosis (MS) patients.

XenoPort To Present At The Morgan Stanley Healthcare Conference

XenoPort, Inc. (Nasdaq:XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Morgan Stanley Global Healthcare Unplugged Conference.